BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 03, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oral interferon-alpha lozenges: Final Phase II data

Final data from a double-blind, Australian Phase II trial in 200 healthy volunteers showed that once-daily oral interferon-alpha lozenges for 16 weeks missed the primary endpoint of significantly reducing the incidence of influenza-like illness vs. placebo (54.5% vs. 62.6%, p=0.25). Oral interferon-alpha lozenges did significantly reduce the incidence of moderate to severe fever and head congestion...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >